Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975

World News: . []

BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent (Patent No. 10,493,047) entitled “Stable Aqueous Capsaicin Injectable Formulations and Medical Uses Thereof,” which provides coverage for the formulation of capsaicin used in the company’s CNTX-4975 product candidate. The patent describes and claims an aqueous, injectable, ready-to-use formulation of capsaicin.

CNTX-4975, the company’s lead product candidate, is an investigational synthetic, proprietary, ultra-pure intra-articular injection of a selective TRPV1 agonist (capsaicin) currently in pivotal clinical trials for the treatment of moderate-to-severe pain associated with knee osteoarthritis (OA).

“We are extremely pleased with the issuance of this patent for CNTX-4975 that supports the easy-to-use, room temperature-stable, prefilled syringe for administration, and believe it is an important milestone for Centrexion,” said Jeffrey B. Kindler, chief executive officer of Centrexion Therapeutics. “As we complete our pivotal clinical trials for CNTX-4975 for moderate-to-severe pain associated with knee OA, this additional protection is an important component in establishing a solid foundation for a successful commercialization plan.”

CNTX-4975 is designed to be administered directly into the joint (intra-articular [IA]) where the pain stimulus originates, and to selectively and locally target and disrupt the signaling of specific TRPV1 pain-signaling nerve fibers within the joint. In January 2018, CNTX-4975 was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of moderate-to-severe pain associated with knee OA. Centrexion has completed patient enrollment in all three studies comprising the Phase 3 VICTORY clinical program and expects to report the results of VICTORY-1 and VICTORY-3 in the first quarter of 2020. Centrexion anticipates reporting the results of the second pivotal trial, VICTORY-2, in the third quarter of 2020.

VICTORY-3 trial is an open label, eight-week trial to evaluate the tolerability of a single IA injection of 1.0 mg of CNTX-4975 in 856 patients with chronic moderate-to-severe pain resulting from knee OA. In addition to expanding the safety database for CNTX-4975, VICTORY-3 is evaluating three patient groups (single painful knee, single painful knee with the opposite knee having a joint replacement, and bilateral painful knee OA where both knees are treated) as well as variations of the procedure pain control technique designed to enable physicians to select options that could best fit their practice dynamics and patient needs if CNTX-4975 is approved.

Patients enrolled in the Phase 3 VICTORY program were permitted to enter the trials on their oral standard of care analgesics for their painful knee OA, such as NSAIDs and an opioid.

More news and information about Centrexion Therapeutics

Published By:

Globe Newswire: 13:00 GMT Tuesday 3rd December 2019

Published: .

Search for other references to "centrexion" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us